HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression - Scorecard - MDSpire

HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression

  • By

  • Juan Wang

  • Kang Wang

  • Zhenhong Hu

  • Xueting Hu

  • May 25, 2026

  • 0 min

Share

Clinical Scorecard: HHLA2: A Novel Immune Checkpoint in Lung Cancer Associated with EGFR Pathway, Macrophage Polarization, and CD8+ T-Cell Metabolism

At a Glance

CategoryDetail
ConditionLung Cancer
Key MechanismsHHLA2 enhances EGFR/MAPK/ERK signaling, promotes macrophage M2 polarization, and suppresses CD8+ T-cell metabolism.
Target PopulationPatients with EGFR-mutant lung cancer.
Care SettingOncology, specifically in the context of lung cancer treatment.

Key Highlights

  • HHLA2 is enriched in EGFR-mutant lung cancer and functions as a genotype-associated immune checkpoint.
  • HHLA2 promotes tumor progression by enhancing EGFR signaling and driving IL-10–dependent macrophage M2 polarization.
  • The HHLA2–KIR3DL3 axis suppresses CD8+ T-cell glutamine metabolism, representing a metabolic immune checkpoint with therapeutic potential.

Guideline-Based Recommendations

Diagnosis

  • Evaluate HHLA2 expression in lung cancer tissues to assess its association with EGFR mutational status.

Management

  • Consider targeting the HHLA2–KIR3DL3 axis in combination with EGFR tyrosine kinase inhibitors for EGFR-mutant lung cancer.

Monitoring & Follow-up

  • Monitor HHLA2 expression as a potential biomarker for treatment response and disease progression.

Risks

  • Lower HHLA2 expression is associated with improved response to neoadjuvant immunotherapy.

Patient & Prescribing Data

Patients with EGFR-mutant lung cancer and potentially those with small cell lung cancer.

HHLA2 expression correlates with tumor size, clinical stage, and overall survival in small cell lung cancer.

Clinical Best Practices

  • Incorporate HHLA2 assessment in the evaluation of lung cancer patients, especially those with EGFR mutations.
  • Utilize HHLA2 as a predictive biomarker for immunotherapy response.

Related Resources & Content

Original Source(s)

HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression

  • by Juan Wang, Kang Wang, Zhenhong Hu, Xueting Hu

  • May 25, 2026

Related Content

Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP

Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer